Allergan fell$. 71 or. 4 percent, to $170.43. Boston Scientific Corp. rose$. 30 or 2.4 percent, to $12.85. Medtronic rose$. 30 or. 5 percent, to $62.71.» Read More
Feb 4- Boston Scientific Corp on Tuesday reported higher-than-expected quarterly results, citing improving demand for its devices that manage irregular heart rhythms. Boston Scientific is also expected to benefit from the introduction of its S-ICD system.
Feb 4- Boston Scientific Corp on Tuesday reported higher-than-expected quarterly earnings on higher sales of its implantable devices that manage irregular heart rhythms. Boston Scientific forecast 2014 earnings of 75 cents to 80 cents a share, excluding special items, on revenue of $7.3 billion to $7.5 billion.
Feb 4- Boston Scientific Corp on Tuesday reported higher fourth-quarter earnings on stronger sales of its implantable devices that manage irregular heart rhythms. The medical device maker said it had earned $108 million, or 8 cents a share, compared with $60 million, or 4 cents a share, a year earlier.
Feb 3- U.S. medical device maker Biomet Inc will pay at least $56 million to settle a multi-district lawsuit relating to defective metal hip replacements, a court filing showed, ending a protracted legal tussle. The lawsuits were combined and jointly heard at the federal court of Indiana, the state where Biomet is headquartered.
Feb 3- Medical device maker Hologic Inc reported a better-than-expected adjusted quarterly profit as it sold more 3 D systems that help detect breast cancer, and its CEO said he would pursue the strategic review started by his predecessor.
Feb 3- Medical device maker Hologic Inc reported a better-than-expected adjusted quarterly profit in part due to higher sales of its 3 D digital mammography systems. Hologic shares rose 4 percent in extended trading.
Feb 3- Medical device maker Hologic Inc reported a better-than-expected adjusted quarterly profit, helped by higher sales of its 3 D digital mammography systems. Hologic shares rose 4 percent in extended trading. Excluding items, Hologic earned 34 cents per share, ahead of analysts' average estimate of 31 cents per share, according to Thomson Reuters I/B/E/S.
The White House is coming under pressure from some of its closest allies to name a CEO to run its health insurance marketplace.
Activist investor Carl Icahn reported a 12.63 stake in medical device maker Hologic, prompting the company to seek protection from a hostile takeover
An entrepreneur has attracted investments from four billionaires: Sam Zell, Herb Simon, David Bonderman and "one family you've never heard of."
Johnson & Johnson and its subsidiaries were accused of promoting powerful psychiatric drugs for unapproved uses in children, seniors and disabled patients.
Pharmaceutical and biotech stocks have outperformed markets this year, and with J&J's second-quarter earnings beat, investors may hope earnings will push stocks even higher.
Americans accustomed to immediate access to the newest technology may be shocked to find that is not the case when it comes to devices that treat ailing hearts.
Keith Smith, Co-founder, Managing Partner at the Surgery Center of Oklahoma says that all funds are channeled to patient care, helping his team deliver quality healthcare and low costs.
Most robotic surgery takes place without a hitch, but a growing number of complaints and lawsuits allege complications and even deaths from Intuitive Surgical's da Vinci device.
If the critics of robotic surgery are right—that safety is an issue—how is that it was performed on 450,000 people last year? The answer may lie in one word: Marketing.
The number of complications from robot-assisted surgery using Intuitive Surgical's da Vinci robot are underreported, allege critics of the procedure, fanning the controversy around the company's pioneering product.
Intuitive Surgical's da Vinci robot was once hailed as a revolution in the operating room, but as more reports of complications have come to light, the da Vinci debate is heating up.
Like all computers, Intuitive Surgical's da Vinci robot can malfunction during surgery. A range of results have been reported by surgeons.
In recent years, as the surgical robot's popularity has grown, so have questions and concerns about its safety, training and the aggressiveness of its marketing.